This study found that SGLT2 immunoexpression was significantly associated with both the tumor stage (pT) and histological grade in patients with PDAC. Well-differentiated adenocarcinoma mainly showed a weak expression of SGLT2, while moderate-to-poorly differentiated cases revealed a moderate to strong immunoexpression for SGLT2. Here, SLC5A2 is linked to adenocarcinoma.